Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer

Summary

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with early diagnosis crucial for improving survival. Due to the absence of effective screening methods, most patients are diagnosed at advanced stages. The population undergoing low-dose computed tomography (LDCT) screening significantly overlaps with those at high risk for PDAC; however, traditional imaging methods have limited sensitivity for detecting pancreatic lesions. This study utilizes the Pancreatic Cancer Detection with Artificial Intelligence (PANDA) system to enhance LDCT for pancreatic cancer screening in a prospective, multicenter, observational cohort. PANDA will analyze LDCT images, followed by a multidisciplinary team (MDT) reassessment of abnormal interpretations. Based on MDT evaluation, individuals will be recalled for further examination, placed under a personalized follow-up plan, or monitored for at least one year. The primary outcomes include pancreatic cancer detection rate, positive predictive value, consensus rate, and recall rate, while secondary outcomes focus on early-stage cancers, resectable tumors, and safety indicators such as false positive rates and unnecessary procedures. This study aims to assess the effectiveness and safety of AI-assisted LDCT for PDAC detection, providing a practical solution for improving public health and enhancing early diagnostic capabilities.

Conditions

• Pancreatic Cancer
• Intraductal Papillary Mucinous Neoplasm
• High-grade Pancreatic Intraepithelial Neoplasia
• PDAC - Pancreatic Ductal Adenocarcinoma
• Mucinous Cystic Neoplasm

Interventions

DIAGNOSTIC_TEST

Diagnostic Evaluation for Positive AI Findings

MDT will review positive AI findings (including PDAC, pancreatic precursor lesions and benign lesion) cases to determine next steps: (1) Suspected PDAC and pancreatic precursor lesions are referred for hospital examination with diagnostic results collected; (2) Benign lesion cases receive personalized monitoring until endpoint events or study end; (3) Cases with positive AI findings but MDT-confirmed normal pancreatic issues receive at least one year of follow-up. If any abnormal results arise, management will transition to either plan (1) or (2).

Sponsors & Collaborators

• Ningbo University Affiliated People's Hospital

  collaborator UNKNOWN

• Jiaxing University Affiliated Second Hospital

  collaborator UNKNOWN

• Meinian Onehealth Healthcare Holdings Co., Ltd

  collaborator UNKNOWN

• Ruici Medical Examination Institution

  collaborator UNKNOWN

• Changhai Hospital

  lead OTHER

Eligibility

Min Age

50 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2025-08-15

Primary Completion

2030-12-30

Completion

2032-12-30

Countries

• China

Study Locations